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What’s already known about this topic? 
• Severe, generalized recessive dystrophic epidermolysis bullosa (RDEB) is marked by 
great morbidity and early death. 
• Currently, no cure exists for RDEB. 
• Bone marrow transplant (BMT) is the only described systemic therapy for RDEB. 
 
What does this study add? 
• First description of post-transplant cyclophosphamide (PTCy) BMT for RDEB. 
• The PTCy BMT platform permits identification of a suitable related donor for most 
patients and for subsequent adoptive transfer of donor non-hematopoietic cells following 
establishment of immunologic tolerance. 
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Summary  
Background   Recessive dystrophic epidermolysis bullosa (RDEB) is a severe systemic 
genodermatosis lacking therapies beyond supportive care for its extensive, life-limiting 
manifestations.  
Objectives   We report the safety and preliminary responses of 10 RDEB patients to bone marrow 
transplant with post-transplant cyclophosphamide (PTCy BMT) following reduced-intensity 
conditioning with subsequent infusions of immunomodulatory donor-derived mesenchymal 
stromal cells (median follow-up of 16 months).  
Methods   BMT toxicities, donor blood and skin engraftment, skin biopsies, medical 
photography, and dynamic assessments of RDEB disease activity by providers and parents were 
obtained at intervals from pre- to 1 year post-BMT. 
Results Related donors varied from haploidentical (n=6) to HLA-matched (n=3) with one HLA-
matched unrelated donor. Transplant complications included graft failure in 3 patients (2 elected 
to pursue 2nd PTCy BMT), veno-occlusive disease in 2, posterior reversible encephalopathy in 1, 
and chronic graft-versus-host disease in 1, the latter deceased. In the 9 ultimately engrafted 
patients, median donor chimerism at 180 days following transplant was 100% in peripheral 
blood, 27% in skin. Skin biopsies show stable (7 of 9) to improved (2 of 9) type VII collagen 
protein expression by immunofluorescence and gain of anchoring fibril components (3 of 9) by 
transmission electron microscopy. Early signs of clinical response include trends toward reduced 
body surface area of blisters/erosions from a median of 49.5% to 27.5% at 100 days following 
BMT (p=0.05), with parental measures indicating stable quality of life.  
Conclusions   PTCy BMT in RDEB provides a means of attaining immunotolerance for future 
donor-derived cellular grafts (trial registered as NCT02582775).  
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Recessive dystrophic epidermolysis bullosa (RDEB) is a clinically heterogeneous 
genodermatosis characterized by COL7A1 mutation(s) yielding inadequate type VII collagen 
(C7) to maintain the integrity of the cutaneous basement and mucosal membranes1-5. The impact 
on an affected individual is skin fragility with cycles of blistering and scarring, acute and chronic 
pain and pruritus, and progressive functional limitations from pseudosyndactyly and joint 
contractions. Systemic manifestations often include gastrointestinal strictures, micronutrient 
deficiencies, anemia of chronic disease, systemic inflammation, and high metabolic demand6, 7. 
Serious infections and development of squamous cell carcinoma (SCC) in adolescence or young 
adulthood limit life expectancy8. The mainstay therapy for RDEB has been supportive care 
attempting to prevent or respond to disease progression9, 10. 
 
The pluripotency of bone marrow cells, including the ability to differentiate along the epithelial 
lineage11-13 and engraft the skin14, prompted investigation of bone marrow transplant (BMT) as a 
cellular source of C7. Following supportive evidence for BMT as a systemic therapy for RDEB 
in a pre-clinical murine model15, our group introduced clinical trials of allogeneic BMT for 
children afflicted with this disease. Initial efforts utilizing fully immunomyeloablative 
chemotherapy demonstrated increased C7 and donor cells in recipient skin following the 
procedure as well as decreased blister formation, but enthusiasm was dampened by regimen-
related toxicity16. Subsequent trials suggested the ability to maintain systemic improvements 
with less toxic, reduced-intensity conditioning regimens17, bolstered by 2 cases of reduced-
intensity conditioning BMT for RDEB reported by others18.  
 
 6 
The critical C7-producing component of the transplant inoculum remains a topic of active 
investigation. Non-hematopoietic mesenchymal stromal cells (MSCs) may play a role as they are 
known to home to sites of tissue damage and inflammation19, 20, contribute to healing21-24, and 
support production of C725, 26. As well as the MSCs infused at the time of BMT, we have 
incorporated additional MSC infusions into the transplant regimen to capitalize on these intrinsic 
qualities. Advances in BMT methodology, including the use of post-transplant 
cyclophosphamide (PTCy), over the past decade now allow for safe use of HLA-haploidentical 
donors (less-than-perfectly HLA-matched siblings or half-matched parents)27-30. While 
previously limited to short-lived third-party, immunogenic MSCs, the PTCy BMT platform 
permits infusion of donor-derived non-hematopoietic cells into an immunologically identical 
recipient at prescribed intervals following BMT. Thus, in principle, the MSCs (derived from the 
same donor as the original BMT) cannot be rejected. Here we report the dermatologic and 
transplant outcomes for the initial 10 patients with RDEB treated with reduced intensity 
conditioning followed by BMT on day 0, PTCy on days +3 and +4, and donor-derived MSCs at 
days +60, +100, and +180. We show that this coordinated cellular therapy is associated with 
acceptable safety and stable donor immunotolerance, the latter necessary for success of future 
donor cellular and tissue graft therapies. 
 
Methods 
Patients and Treatment 
Pediatric (age <18 years) patients with RDEB undergoing PTCy BMT at the University of 
Minnesota between April 2016 and July 2017, with a minimum of 6 months of follow-up, were 
identified from a prospectively recorded Blood and Marrow Transplant Database of 
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demographic, clinical, and laboratory outcome measures. In accordance with the Declaration of 
Helsinki, all parents/guardians signed an Institutional Review Board-approved informed consent. 
As MSCs are not approved for clinical use by the Food and Drug Administration, this regimen is 
provided as an investigational new drug (IND #14166), registered as study NCT02582775 at 
ClinicalTrials.gov. 
 
Patients eligible for PTCy BMT had confirmed diagnoses of RDEB by mutation analysis of 
COL7A1, reduced or absent IF staining for C7, lack of normal C7-supported ultrastructural 
basement membrane components visualized by IEM on skin biopsy, and a clinical history 
demonstrating generalized severe RDEB. Each case was de-identified and comprehensively 
assessed by an international external advisory panel composed of three EB experts (External 
Advisory Panel: JAM, AH, KT) to assess whether disease severity predicted a poor quality of 
life and threatened survival with the risk of SCC and serious infection, thus warranting 
therapeutic intervention.  
 
PTCy BMT details including preparation for, eligibility/exclusion criteria, donor selection, 
conditioning regimen (rabbit anti-thymocyte globulin, cyclophosphamide, fludarabine, and low-
dose total body irradiation), GvHD prophylaxis (PTCy, mycophenylate mofetil, ± tacrolimus), 
and supportive care are described in the Supplemental Materials and Supplemental Figure 2. 
Transplant outcomes include time to engraftment of neutrophils, defined as the first of 3 
consecutive days of an absolute neutrophil count ≥0.5 × 109/L, and platelets, defined as the first 
of 3 consecutive days of a platelet count ≥20 × 109/L independent of platelet transfusion in the 
prior 7 days. GvHD was scored using standard criteria31. 
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Disease assessments 
At baseline, and at days +100, +180, and +365 post-PTCy BMT, comprehensive medical 
photography, laboratory assessments of inflammation (C-reactive protein, erythrocyte 
sedimentation rate), and perilesional skin biopsies of extremities were taken. Full thickness skin 
biopsies were assessed as previously described16, including IF for C7 presence [using 6 C7 
antibodies: Woodley, Sigma LH7.4, Abnova, Calbio, Abcam, and Clone 185, with controls 
including fibrillin and collagen IV (Col4)], transmission electron microscopy and IEM for 
basement membrane ultrastructure, particularly assessment of C7-forming AFs. Whole DNA 
from a full-thickness skin biopsy was also subjected to variable number of tandem repeats 
analysis to determine donor contribution. Peripheral blood donor chimerism was assessed 
concurrently (as well as on day +28).  
 
Both provider/clinician and parent components of the validated Instrument for Scoring Clinical 
Outcome of Research for Epidermolysis Bullosa (iscorEB)32, 33 were completed at baseline, and 
at days +100, +180, and +365 post-PTCy BMT. The iscorEB was preferred to other EB-specific 
disease scales as it quantifies longitudinal changes with emphasis on dynamic wound healing as 
opposed to fixed scar disease components. Provider subscores include assessment of BSA of 
involvement as well as extent (blisters, erosions, scabbing, chronic wounds, and infection); 
mucosal involvement of mouth, airway, and eye; internal organ involvement as reflected in 
nutrition, urogenital, or cardiac complications; laboratory abnormalities; and complications 
including SCC, osteopenia, unscheduled hospital visits, and need for procedures such as 
esophageal dilatations. Parent subscores highlight quality of life measures including pain, 
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pruritus, essential functions (ability to eat, drink, and void), sleep disturbance, daily activities 
(mobility and use of hands), mood, and overall impact of the disease on the ability to participate 
in school and leisure activities. 
 
Analyses 
All analyses are descriptive with formal group comparisons over time by non-parametric paired 
tests (Wilcoxon signed rank test) using GraphPad Prism 7.0, La Jolla, CA. 
 
Results 
Patient characteristics 
Ten patients underwent a total of 12 reduced intensity PTCy BMTs between April 2016-July 
2017, with a median follow-up of 16 months (range 8-24 months; enrollment data in 
Supplemental Figure 1). Donors included 3 haploidentical siblings, 2 haploidentical mothers, 4 
HLA-matched siblings, and one HLA-matched unrelated individual. Characteristics of the 
patients, donors, and transplant regimens are described Supplemental Table 1. Of note, patient 
3 had previously undergone an unrelated donor BMT complicated by graft failure (1 year prior to 
PTCy BMT). Initial hospital discharge occurred at a median of 27 days post-BMT (range 22-61 
days). In the first 100 days following all 12 BMTs, 9 patients required readmission for an 
additional 5 days (median, range 2-27 days). 
 
Outcomes 
The dermatologic outcomes of PTCy BMT for RDEB are summarized below, with individual 
patient results provided in Table 1.  
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Body surface area, blister formation, laboratory measures of inflammation 
Disease modulation following PTCy BMT was captured by interval assessments of quantitative 
measures including body surface area (BSA) involvement (of blisters and erosions), skin fragility 
as measured by blister time, laboratory markers of inflammation. BSA for donor engrafted 
patients declined from a median of 49.5% [interquartile range (IQR) =24-65.5] at baseline to 
27.5% (IQR=16.3-35.8, n=9, p=0.05) at day +100, though failed to reach statistical significance. 
Later comparisons were limited by small numbers of patients with median BSA of 35.8% 
(IQR=14.8-48.5, n=8) at day +180 and 12% (IQR=10-22.5, n=3) at day +365. Conversely, for 
the 3 patients with graft failure, BSA increased from a median of 37.5% (range 33-67.5%) at 
baseline to 41% at day +60 (range 14-73.5%, n=3) and 62% at day +180 (range 50-73.5%, n=2, 
both subsequently re-transplanted). Time to induced blister formation (p=0.94), C-reactive 
protein (p=0.40), and erythrocyte sedimentation rate (p=0.88) were unchanged on paired 
comparisons from baseline to day +180.  
 
C7 immunofluorescence and ultrastructural examination of skin 
Each patient had skin biopsies at baseline (n=10), day +100 (n=9), +180 (n=9; epidermal loss 
upon sampling occurred in 2), and 1 year (n=3). Samples were assessed by 6 IF stains against C7 
as well as by IEM. Figure 1 highlights the medical photography, IF, and IEM results of Patient 
1, comparing baseline to day+180 following PTCy BMT, with Supplemental Figure 2 showing 
IF results over time for each donor-engrafted patient (2nd transplant time points for Patients 2 
and 6, Patient 5 excluded as no follow-up biopsies available for comparison). No patient 
demonstrated persistent loss in the number of positive C7 antibodies, 1 had gain of 1 additional 
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positive C7 antibody over time, and 1 demonstrated qualitative increase in the brightness of 2 C7 
immunostains. Transmission electron microscopy with the addition of IEM revealed 
improvements in 4 of 9 donor-engrafted patients; 3 with gain of primitive anchoring fibril (AF) 
components and 4 with increases in C7 immunostaining. While no structurally normal, complete 
AFs were identified in these early post-PTCy BMT evaluations, the day +180 skin biopsy of 
Patient 1 showed promising ultra-structural evolution of the cutaneous basement membrane. C7 
immunostaining labeled both hemidesmosomes and newly seen primitive AF components.  
 
Quality of life reports 
IscorEB (Instrument for Scoring Clinical Outcome of Research for Epidermolysis Bullosa), a 
validated measure of combined clinical/laboratory domains (medical provider sub-score) and 
quality of life domains (parent sub-score), was completed for each patient prior to and at 
intervals following PTCy BMT (d+100, +180, +365), as described in the methods. Provider sub-
scale scores are shown for each individual patient in Table 1, and parental assessments of quality 
of life in Figure 2. While we detected no statistically significant changes in perceived disease 
severity over the first year following PTCy BMT, declines from baseline to day +365 were 
observed in pain (32.5% of maximum severity to 20%), pruritus (75% of maximum severity to 
50%), and sleep disturbance (62.5% of maximum severity to 25%) sub-scores. 
 
Donor graft function 
Three of the first 6 patients (Patients 2, 5, and 6) had primary, non-neutropenic graft failure with 
autologous hematopoietic recovery and no evidence of donor cells in peripheral blood or skin, 
suggestive of inadequate immune suppression from myeloablation. Two had evidence of 
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immune-mediated graft rejection with panel reactive antibody testing prior to transplant 
revealing moderate risk [mean fluorescence intensity (MFI) of 1000-3000] HLA class I donor-
specific antibodies (two for Patient 2 and one for Patient 5). For subsequent patients, the 
threshold for clinical relevance of anti-HLA antibody MFI was lowered from 3000 to 1000 and 
the conditioning regimen was amended to increase total body irradiation (TBI) from 300 cGy to 
400 cGy (Supplemental Figure 3). Two patients with graft failure were re-transplanted with the 
same donors after 6-month recovery intervals from initial PTCy BMT; one declined additional 
therapy. Since increasing the TBI dose and increasing attention to pre-transplant recipient anti-
HLA antibody assessments, there has been no graft failure. At the same time, subsequent donors 
have been HLA-matched related siblings.  
 
Donor chimerism 
Donor chimerism in peripheral blood and skin are shown for each patient in Supplemental 
Table 1. Excluding the 3 cases of graft failure, median donor myeloid and lymphoid peripheral 
blood chimerism are 100% in both compartments at days +180 (n=9, myeloid range 28-100%, 
lymphoid range 52-100%) and +365 (n=3; myeloid range 90-100%, lymphoid range 76-100%). 
Donor chimerism in skin for the same patients is a median of 27% (range 7-58%) at day +180 
and 11% (range 6-34%) at day +365.  
 
Serious adverse events 
Serious adverse events following PTCy BMT were limited, with 2 of 12 transplants complicated 
by veno-occlusive disease of the liver, both successfully treated with defibrotide, and one case of 
posterior reversible encephalopathy, which resolved. No acute graft-versus-host disease (GvHD) 
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was identified. No toxicities have been observed with MSC infusions. Following his second 
PTCy BMT, Patient 6 never achieved platelet recovery despite trials of thrombopoietin receptor 
agonists and a CD34+ selected peripheral blood donor stem cell boost. At 7 months post-PTCy 
BMT, a bone marrow biopsy demonstrated 40-50% cellularity with normal trilineage 
hematopoiesis. He additionally suffered hyperbilirubinemia and bouts of severe nausea, both 
persistent despite cholecystectomy and in the absence of etiology from liver and stomach 
biopsies. Given his constellation of symptoms, he began therapy for chronic GvHD on day +216. 
On day +356, he died of multi-drug resistant Pseudomonal sepsis.  
 
Discussion 
Most of what we understand today about BMT for RDEB comes from patient by patient analysis 
of the complex dynamics of engraftment and persistence of traditional allogeneic BMT15-18, 34. 
However, HLA-matched unrelated and related (typically sibling) donor BMT has been 
associated with significant physical (from chemotherapy and radiation) and immune 
(exemplified by GvHD) side effects. The ethical dilemma for clinicians and families considering 
BMT for their patient or child demands that the near-term morbidity and mortality risks be 
outweighed by the potential for lifelong benefits of novel therapies in this devastating disorder. 
Here, we show that PTCy BMT is feasible in individuals with generalized severe RDEB, with 
acceptable safety to recipients, very low rates of acute (0%) and chronic (10%, n=1) GvHD, with 
achievement of sustained donor tolerance. 
 
Our present results propose that, in addition to quantitatively expanding the pool of available 
donors, PTCy BMT can provide yet-unexplored quality to the traditional BMT: adoptive transfer 
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of non-hematopoietic cells with long-term extra-medullary engraftment potential. In the present 
study, we have integrated clinical (BSA, skin photographs), histological (IF), ultra-structural 
(transmission electron microscopy and IEM), laboratory (donor engraftment, inflammatory 
markers) and quality of life (iscorEB) data to analyze the metrics of clinical efficacy supported 
by structural tissue correlates. We showed that donor cells engrafted in recipient skin (median of 
27% at 6 months after PTCy BMT) and skin involvement decreased (BSA decreased from a 
median of 45.5% before PTCy BMT to 16.5% at 6 months after PTCy BMT). While all patients 
undergoing BMT may benefit from excellent hospital-based skin care, periods of decreased 
mobility-induced trauma, and anti-inflammatory effects of conditioning and immune 
suppression, two of 3 patients with graft failure demonstrated substantial increases in BSA from 
baseline pre-PTCy BMT to 60, 100, and 180 days post-PTCy BMT. The safety of HaploBMT 
has been greatly enhanced by recent addition of PTCy (as in the present study), eliminating the 
most alloreactive T-cell clones (and thus dramatically reduces the immune complications of 
BMT, such as GvHD). Of note, we observed no acute and only one case of chronic GvHD in the 
present study. 
 
We acknowledge several limitations to this study. Outcomes are largely descriptive given the 
rarity of RDEB and subsequent small study cohort. Only 3 of 10 patients reside in the U.S., none 
local to our medical facility. Timely follow-up of international patients has both financial and 
political barriers. Reporting clinical outcomes with a median follow-up of 16 months (range 8-
24) may not capture the full response to BMT, the trajectory and stability of which would best be 
described with greater follow-up. The skin fragility of RDEB makes measurements of clinical 
response to PTCy BMT challenging. Dressing changes are complex, often with associated pain 
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and separated over several days, which limits whole-body, high-quality medical photography of 
the skin. Intrinsic separation at the dermal-epidermal junction limits skin biopsy integrity. Skin 
donor chimerism is not limited to C7-producing donor cells, but may include donor immune 
infiltrates responding to cutaneous infections or contributing to local recovery following tissue 
damage. 
 
While our present results highlight a role for three doses of systemically administered MSCs, our 
data have several other practical applications. These include the ability of the PTCy BMT 
platform to accommodate maintenance infusions of MSCs in any combination of intravenous and 
local (intra-dermal or intra-mucosal) delivery of MSCs, infusion/injection of alternative cells 
(such as fibroblasts and keratinocytes) and tissue grafts (such as skin, mucosa, and corneal 
epithelium)—all relevant for treatment of the wounds and systemic manifestations of RDEB.  
 
To our knowledge, this is the first attempt to generate an immunologically synchronous recipient 
for extramedullary engraftment of non-hematopoietic cells. We acknowledge lack of direct donor 
hematopoietic C7 production or contribution to new AFs limits the efficacy of isolated BMT. 
However, our work proposes PTCy BMT as a viable platform for comprehensive, multi-modal 
systemic therapies aimed at decreasing the morbidity and mortality of RDEB. Future studies will 
expand upon these findings, extending follow-up to monitor the impact of PTCy BMT on skin 
integrity (including development of AFs), SCC, and overall survival; incorporating other 
promising donor cellular therapies and/or epidermal grafting; and exploring safety and 
effectiveness in PTCy BMT for additional forms of debilitating EB.  
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TABLE 1a. PTCy BMT Dermatologic Outcomes 
 Patient 1 Patient 2  1st HaploBMT               2nd HaploBMT Patient 3 Patient 4 Patient 5 
Patient: Sex, 
Col7A1 
mutation(s), 
Age at BMT 
Female 
c.8201G>A, c.8528-1G>A 
8.2 years 
Male 
c.425A>G, c.5797C>T 
3.1 years  3.6 years 
Female 
c.6501+1G>C, c.7787del 
22 months 
Female 
c.6527dupC, c.6527dupC 
22 months 
Male 
c.611T>C, delexon25-52 
11.5 years 
Clinical 
features1 
Esophageal narrowing, 
pseudosyndactyly, Constipation 
Oral blisters, corneal ulcers/abrasions, beginning 
fusion of toes Oral blistering Mucosal blistering & erosions 
Oral lesions, dysphagia, 
constipation, corneal 
abrasions, dental caries 
IF 
interpretation  
6/6 anti-C7 stains positive at baseline, 
d+100, 180, 365; 
2 anti-C7 stains with increased brightness 
and extension from the basement 
membrane to the dermis from d+180 
onward 
2/6 anti-C7 stains positive at baseline until d+100 
following 2nd HaploBMT; Increased to 3/6 with 
additional 1 anti-C7 stain with increased brightness 
and extension from the basement membrane to the 
dermis at d+180 
3/6 anti-C7 stains positive at 
baseline, d+100, 180, 365; 
No change over time 
6/6 anti-C7 stains positive at 
baseline, d+100, 180, 365;  
No change over time  
6/6 anti-C7 stains positive at 
baseline, no subsequent skin 
biopsies for comparison 
EM 
interpretation 
 
  
AFs: filamentous/wispy, slight 
banding/arching (d+180); 
C7 immunolabeling: very light (d0)  
moderate, associated with 
hemidesmosomes and AFs (d+180) 
  
No AFs or C7 immunolabeling detected (d+180) 
 
AFs: none (d0)  occasional 
linear projections (d+180); 
C7 immunostaining from 
none (d0)  very light 
(d+180) 
AFs: none (d0)  occasional 
linear projections (d+365); 
C7 immunostaining: very 
light with 1 antibody (d0)  
2 antibodies (d+365) 
N/A 
BSA 
involvement 
(%) × 
BMT day 
            
Blister time  
(minutes) × 
BMT day 
           
Provider 
iscorEB 
(max 137) ×  
BMT day 
 
            
Current status, 
Time since BMT Alive, 24 months Alive, 17 months from 2
nd HaploBMT Alive, 20 months Alive, 20 months Alive, 19 months 
1All patients: skin surface covered with erosions and blisters; history of pruritus and pain.  
PTCy, post-transplant cyclophosphamide; haplo, haploidentical; BMT, bone marrow transplant; IF, immunofluorescence; C7, collagen VII; EM, electron microscopy; AFs, anchoring fibrils; BSA, body surface 
area; iscorEB, Instrument for Scoring Clinical Outcome of Research for Epidermolysis Bullosa.  
Graft failure, 
Autologous 
recovery 
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TABLE 1b. PTCy BMT Dermatologic Outcomes 
 
 Patient 6 1st HaploBMT          2nd HaploBMT Patient 7 Patient 8 Patient 9 Patient 10 
Patient: Sex, 
Col7A1 
mutation(s), 
Age at BMT 
Male 
c.7723G>A, c.6236G>T 
16.3 years16.9 years 
Male 
c.3140-1G>A, c.3140-1G>A 
6.4 years 
Female 
c.3140-1G>A, c.3140-1G>A 
22.1 years 
Male 
c.4738_4740delinsA, c.425A>G 
12.2 years 
Female 
c.5888G>A, c.5888G>A 
12.8 years 
Clinical 
features1 
Mucosal erosions, contractures, corneal 
abrasion, dental carries, osteoporosis, FTT 
  
Esophageal strictures, dental 
carries, microstomia & 
ankyloglossia, nail loss, anemia, 
mild contractures 
  
  
Esophageal strictures, dental 
carries, microstomia & 
ankyloglossia, nail loss, anemia, 
moderate contractures 
Esophageal strictures, 
constipation, anemia, 
contractures, nail loss 
  
Corneal abrasions, esophageal 
stenosis, dental carries, anemia, 
FTT, contractures, nail loss, 
depression 
IF 
interpretation  
6/6 anti-C7 stains positive at baseline, d+100, 
180 following 2nd HaploBMT;  
No change over time 
3/6 anti-C7 stains positive at 
baseline, d+100 (d+180, 
epidermis lost in procedure);  
No change over time 
  
3/6 anti-C7 stains positive at 
baseline, d+100 (d+180, 
epidermis lost in procedure);  
2 anti-C7 stains less bright at 
d+100 
  
3/6 anti-C7 stains positive at 
baseline, 2 lost at d+100 but 
regained for again 3/6 anti-C7 
stains positive at d+180 
3/6 anti-C7 stains positive at 
baseline, d+100, 180;  
No change over time 
EM 
interpretation 
No AFs or C7 Immunolabeling detected 
(d+180) 
No AFs or C7 Immunolabeling 
detected (d+180) 
  
No AFs (d0, d+180); C7 
immunostaining from none (d0) 
 very light (d+180) 
  
No AFs or C7 Immunolabeling 
detected (d+180) 
Possible AFs (d0, d+180), C7 
immunolabeling absent 
BSA 
involvement 
(%) × 
BMT day 
          
Blister time  
(minutes) × 
BMT day 
          
Provider 
iscorEB 
(max 137) ×  
BMT day 
 
           
Current status, 
Time since BMT Died, 11 months from 2
nd HaploBMT Alive, 14 months Alive, 13 months Alive, 8 months Alive, 8 months 
1All patients: skin surface covered with erosions and blisters; history of pruritus and pain.  
PTCy, post-transplant cyclophosphamide; haplo, haploidentical; BMT, bone marrow transplant; FTT, failure to thrive; IF, immunofluorescence; C7, collagen VII; EM, electron microscopy; AFs, anchoring 
fibrils; BSA, body surface area; iscorEB, Instrument for Scoring Clinical Outcome of Research for Epidermolysis Bullosa. 
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FIGURE LEGENDS 
 
Figure 1. Dermatologic outcomes. Select photographs, demonstrating dermatologic 
involvement of EB, and skin biopsy results, including immunofluorescence [40× magnification 
merged dapi (blue) and C7 collagen antibody (red)] and immunoelectron microscopy 
[transmission electron microscopy with C7 collagen-directed immunostain (black)], shown for 
Patient 1 at baseline and day +180 after transplantation. 
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Figure 2. Quality of life: iscorEB parent reports. The median and interquartile ranges are of 
parent iscorEB sub-scores are displayed at PTCy BMT time points as labeled (baseline, n=12; 
day +100, n=11; day 180, n=10; and day +365, n=3). 
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SUPPLEMENTAL MATERIALS: PTCy BMT details 
Prior to PTCy BMT, patients underwent gastrostomy tube placement to optimize nutrition, 
provide a mechanism to reduce nausea/vomiting during transplant that may contribute to 
esophageal stricture formation, and allow for enteral administration of medications. Eligibility to 
proceed to BMT included adequate major organ function—including renal glomerular filtration 
rate within normal range for age, liver function tests and bilirubin <5× the upper limit of normal, 
adequate pulmonary function (by pulmonary function testing if age appropriate, or by history and 
physical exam), normal electrocardiogram and echocardiogram showing left ventricular ejection 
fraction ≥45%. Sexually active patients must agree to use adequate birth control from the time of 
conditioning until 1 year following transplant, and pregnant or breast-feeding patients were 
excluded. Finally, evidence of squamous cell carcinoma, history of HIV infection, or active, 
untreated systemic infection at the time of transplant (or any mold infection in the prior 30 days) 
rendered a patient ineligible for BMT. 
 
PTCy BMT required identification of a stem cell donor, typically related, matching the patient on 
at least one of two alleles at any given HLA locus. In the absence of an 8/8 HLA-matched sibling 
donor, patients were also tested for the presence of donor-specific antibodies (DSA, circulating 
anti-HLA antibodies specific to the donor HLA). When more than one donor was considered, 
selection was informed by donor-specific antigen negativity, as well as preference for younger 
age, nulliparous, ABO-compatible, and cytomegalovirus (CMV) serostatus consistent with that 
of the patient.  
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The initial 6 patients undergoing PTCy BMT received the following conditioning regimen 
(Supplemental Figure 2): rabbit anti-thymocyte globulin (rATG), pre-medicated with 
methylprednisolone, acetaminophen, and diphenhydramine, infused at a dose of 0.5 mg/kg 
recipient weight intravenously (IV) on day -9 prior to BMT, then 2 mg/kg/dose IV on days -8 
and -7; fludarabine 30 mg/m2 recipient body-surface-area/day IV on days -6 to -2; 
cyclophosphamide 14.5 mg/kg/dose IV on days -6 and -5 (with mesna for uroprotection); and a 
single fraction of low-dose total body irradiation (TBI) of 300 cGy on day -1. With graft failure 
and autologous recovery of hematopoiesis noted in 3 of the first 6 patients receiving this 
regimen, immunomyeloablation was escalated by increasing the dose of TBI to two fractions of 
200 cGy (total of 400 cGy) on day -1.  
 
On day 0, all patients were infused fresh, un-irradiated, donor bone marrow, filtered to remove 
any bone fragments. Donor-recipient blood type mismatch, when present, prompted red blood 
cell depletion of the bone marrow. Methylprednisolone, acetaminophen, and diphenhydramine 
premedication was provided. For each patient, the goal total nucleated cell count was 2-10 × 
108/kg of recipient’s ideal body weight. In the situation where a cryopreserved donor umbilical 
cord was available to supplement, it was thawed and infused.  
 
With donor consent, an additional 30 mL of bone marrow was collected for expansion of donor-
derived MSCs. Once expanded in adequate numbers, an aliquot of the MSCs were tested for 
sterility, epitope analysis, and differentiation potential, while the remainder was cryopreserved in 
doses of approximately 2 × 106/kg recipient weight. At days +60, +100, and +180 following 
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PTCy BMT, MSC doses meeting lot release criteria were infused intravenously, and patients 
were monitored for any infusion reactions. 
 
Graft-versus-host disease (GvHD) prophylaxis included infusion of PTCy 50 mg/kg recipient 
weight on days +3 and +4 following BMT, with hyperhydration and mesna for uroprotection. In 
the absence of acute GvHD, all patients received mycophenylate mofetil 15 mg/kg/dose IV every 
8 hours from day +5 to +35 or 7 days following neutrophil recovery (defined as an absolute 
neutrophil count of >0.5 × 109/L for 3 consecutive days), whichever occurred later. Tacrolimus 
was provided from day +5 to +100, initially as a continuous infusion, then transitioned to twice 
or thrice daily oral dosing to achieve a target trough of 5-10 μg/L. In the absence of acute GvHD, 
tacrolimus was tapered off over 10 weeks starting at day +101. Planned tacrolimus was omitted 
from GvHD prophylaxis for HLA-identical sibling donor recipients; however, it was added in 
cases of engraftment syndrome. 
 
Supportive care for PTCy BMT included hospitalization in single occupancy, high-efficiency 
particulate air-filtered rooms with use of antibiotic prophylaxis through neutrophil engraftment. 
Anti-fungal and anti-viral (targeting CMV and HSV as appropriate) prophylaxis was provided 
until at least day +100, with prophylaxis against Pneumocystis jiroveci pneumonia following 
engraftment until one year post-BMT. Antibiotic coverage was broadened empirically with fever 
and adjusted based on infection surveillance. Blood product transfusions were CMV-safe. 
Granulocyte colony-stimulating factor has been provided in cases of slow blood cell count 
recovery. Patients were screened by blood CMV PCRs weekly until day +100. Intensive skin 
care including continuous assessment, lancing of blisters with sterile needles, and dressing 
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changes/bathing 2-3×/week, was tailored to each patient based on history and response to 
transplant-associated fluid shifts and skin infections. Central line dressings were changed at a 
minimum of weekly, often more frequently depending on visual inspection. Pain management 
for baseline EB wound-associated pain and pruritus, as well as for BMT mucositis, was also 
patient-dependent and provided with the assistance of a Pediatric Advanced and Complex Care 
Team. 
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Supplemental Table 1a. PTCy BMT characteristics and outcomes 
 
 Patient 1 Patient 2  1st HaploBMT                         2nd HaploBMT Patient 3 Patient 4 Patient 5 
Patient: Sex, 
Col7A1 
mutation(s), 
Age at BMT 
Female 
c.8201G>A, c.8528-1G>A 
8.2 years 
Male 
c.425A>G, c.5797C>T 
3.1 years  3.6 years 
Female 
c.6501+1G>C, c.7787del 
22 months 
Female 
c.6527dupC, c.6527dupC 
22 months 
Male 
c.611T>C, delexon25-52 
11.5 years 
Donor: Stem 
cell source, 
HLA match, 
DSA status 
Sister BM, 5/10, no DSA Mother BM, 5/10, no DSA Sister BM, 6/10, no DSA Unrelated BM, 8/8,  no DSA Sister BM, 5/10, no DSA 
Conditioning 
regimen 
 
 
 
GvHD 
prophylaxis 
Fludarabine 150 mg/m2 
Cyclophosphamide 29 mg/kg 
rATG 4.5 mg/kg 
TBI 300 cGy 
 
PTCy 50 mg/kg/d on d+3, +4 
Tacrolimus, MMF 
Fludarabine 150 mg/m2 
Cyclophosphamide 29 mg/kg 
rATG 4.5 mg/kg 
TBI 300 cGy 
 
PTCy 50 mg/kg/d on d+3, +4 
Tacrolimus, MMF 
Fludarabine 150 mg/m2 
Cyclophosphamide 29 mg/kg 
TBI 200 cGy 
 
PTCy 50 mg/kg/d on d+3, +4 
Tacrolimus, MMF 
Fludarabine 150 mg/m2 
Cyclophosphamide 29 mg/kg 
rATG 4.5 mg/kg 
TBI 300 cGy 
 
PTCy 50 mg/kg/d on d+3, +4 
Tacrolimus, MMF 
Fludarabine 150 mg/m2 
Cyclophosphamide 29 mg/kg 
rATG 4.5 mg/kg 
TBI 300 cGy 
 
PTCy 50 mg/kg/d on d+3, +4 
Tacrolimus, MMF 
Fludarabine 150 mg/m2 
Cyclophosphamide 29 mg/kg 
rATG 4.5 mg/kg 
TBI 300 cGy 
 
PTCy 50 mg/kg/d on d+3, +4 
Tacrolimus, MMF 
BMT dose:  
TNC 
CD34+  
 
7.05 × 108 
30.38 × 106 
 
13.25 × 108 
11 × 106 
 
7.25 × 108 
6.26 × 106 
 
7.08 × 108 
19.95 × 106 
 
7.25 × 108 
7.39 × 106 
 
8.19 × 108 
21.3 × 106 
MSC doses2 Days +60, +100, +180 Days +60, +100  (to 2nd BMT) Days +60, +100, +180 Days +60, +100, +180 Days +60, +100, +180 
Days +60, +100  
(home prior to d+180) 
Neutrophil, 
Platelet 
recovery 
Day +19, 
Day +47 
Day +26, 
Day +31 
Day +15, 
Day +19 
Day +16, 
Day +22 
Day +17, 
Day +22 
Day +19, 
Day +24 
Severe adverse 
events3 VOD, PRES None None None None None 
GvHD None None None None None None 
% Donor 
Chimerism 
× BMT day 
 
 
   
    
1All patients had: skin surface covered with erosions and blisters; history of pruritus and pain. 2intravenous doses of 2 × 106 donor-derived MSCs/kg recipient weight. 3Serious adverse events restricted to non-
hematologic, non-infectious, non-dermatologic adverse events through engraftment, unexpected adverse events, and MSC-targeted toxicities. 
 
PTCy, post-transplant cyclophosphamide; haplo, haploidentical; BMT, bone marrow transplant; HLA, human leukocyte antigen; DSA, donor specific antibodies; BM, bone marrow; N/A, not applicable; GvHD, 
graft-versus-host disease; rATG, rabbit anti-thymocyte globulin; TBI, total body irradiation; MMF, mycophenylate mofetil; TNC, total nucleated cells/kg recipient weight; CD34+, CD34+ cells/kg recipient 
weight; MSC, mesenchymal stromal cell; VOD, veno-occlusive disease; PRES, posterior-reversible encephalopathy syndrome; PB, peripheral blood. 
  
Graft failure, 
Autologous 
recovery 
Graft failure, 
Autologous 
recovery 
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Supplemental Table 1b. PTCy BMT characteristics and outcomes 
 
 Patient 6 1st HaploBMT                           2nd HaploBMT Patient 7 Patient 8 Patient 9 Patient 10 
Patient: Sex, 
Col7A1 
mutation(s), 
Age at BMT 
Male 
c.7723G>A, c.6236G>T 
16.3 years16.9 years 
Male 
c.3140-1G>A, c.3140-1G>A 
6.4 years 
Female 
c.3140-1G>A, c.3140-1G>A 
22.1 years 
Male 
c.4738_4740delinsA, 
c.425A>G 
12.2 years 
Female 
c.5888G>A, c.5888G>A 
12.8 years 
Donor: Stem 
cell source, 
HLA match, 
DSA status 
Mother BM, 5/10 
Moderate risk DSA positive  no DSA 
Brother BM, 10/10,  
DSA N/A 
Sister BM, 10/10,  
DSA N/A 
Sister BM, 10/10,  
DSA N/A 
Sister BM, 10/10,  
DSA N/A 
Conditioning 
regimen  
 
 
 
GvHD 
prophylaxis 
Fludarabine 150 mg/m2 
Cyclophosphamide 29 mg/kg 
rATG 4.5 mg/kg 
TBI 300 cGy 
 
PTCy 50 mg/kg/d on d+3, +4 
Tacrolimus, MMF 
Fludarabine 150 mg/m2 
Cyclophosphamide 29 mg/kg 
rATG 4.5 mg/kg 
TBI 300 cGy 
 
PTCy 50 mg/kg/d on d+3, +4 
Tacrolimus, MMF 
Fludarabine 150 mg/m2 
Cyclophosphamide 29 mg/kg 
rATG 4.5 mg/kg 
TBI 400 cGy 
 
PTCy 50 mg/kg/d on d+3, +4 
MMF 
Fludarabine 150 mg/m2 
Cyclophosphamide 29 mg/kg 
rATG 4.5 mg/kg 
TBI 400 cGy 
 
PTCy 50 mg/kg/d on d+3, +4 
Tacrolimus, MMF 
Fludarabine 150 mg/m2 
Cyclophosphamide 29 mg/kg 
rATG 4.5 mg/kg 
TBI 400 cGy 
 
PTCy 50 mg/kg/d on d+3, +4 
MMF 
Fludarabine 150 mg/m2 
Cyclophosphamide 29 mg/kg 
rATG 4.5 mg/kg 
TBI 400 cGy 
 
PTCy 50 mg/kg/d on d+3, +4 
MMF 
BMT dose: 
 TNC 
 CD34+ 
5.56 × 108 
3.11 × 106 
 
4.10 × 108 
1.8 ×106 
(& Day+123: CD34+ PB 
boost) 
4.83 × 108 
11.94 × 106 
6.05 × 108 
5.33 × 106 
3.85 × 108 
4.78 × 106 
4.62 × 108 
6.52 × 106 
MSC doses2  Days +60, +100 (to 2nd BMT) 
Days +60, +100 
(additional MSCs failed to 
meet release criteria) 
Days +60, +100, +180 Days +60, +100, +180 Days +60, +100, +180 Days +60, +100, +180 
Neutrophil, 
Platelet 
Recovery 
Day +31, 
Day +49 
Day +29, 
Not achieved 
Day +15, 
Day +32 
Day +15, 
Day +22 
Day +17, 
Day +28 
Day +25, 
Day +63 
Severe adverse 
events3 None None None None None VOD 
GvHD None 
Chronic GvHD (severe, dx 
day+216 on tx until death) 
Died day+356 of multi-drug 
resistant Pseudomonas sepsis 
None None None None 
% Donor 
Chimerism 
× BMT day 
 
 
       
1All patients had: skin surface covered with erosions and blisters; history of pruritus and pain. 2Intravenous doses of 2 × 106 donor-derived MSCs/kg recipient weight. 3Serious adverse events restricted to non-
hematologic, non-infectious, non-dermatologic adverse events through engraftment, unexpected adverse events, and MSC targeted toxicities.  
 
PTCy, post-transplant cyclophosphamide; haplo, haploidentical; BMT, bone marrow transplant; FTT, failure to thrive; HLA, human leukocyte antigen; DSA, donor specific antibodies; BM, bone marrow; N/A, 
not applicable; GvHD, graft-versus-host disease; rATG, rabbit anti-thymocyte globulin; TBI, total body irradiation; MMF, mycophenylate mofetil; TNC, total nucleated cells/kg recipient weight; CD34+, CD34+ 
cells/kg recipient weight; PB, peripheral blood; MSC, mesenchymal stromal cell; VOD, veno-occlusive disease; dx, diagnosed; tx; treatment. 
 
Graft failure, 
Autologous 
recovery 
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SUPPLEMENTAL FIGURE LEGENDS 
 
Supplemental Figure 1. Protocol enrollment. Flow diagram of RDEB patients from eligibility 
assessment to enrollment and PTCy BMT.  
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Supplemental Figure 2. Collagen VII immunofluorescence of the dermal-epidermal 
junction. For each RDEB patient with available skin biopsies over time (a, patients 1-4; b, 
patients 6-10; patient 5 had graft failure and is not shown), baseline, day +180 (or day +100 if 
day +180 biopsies lacked epidermis), and day +365 (where available) are shown [40× 
magnification merged dapi (blue) and C7 collagen antibody (red)]. C7 antibodies include 
Woodley, Sigma LH7.4, Abnova, Calbio, Abcam, and Clone 185, with controls including 
fibrillin and collagen IV (Col4). 
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Supplemental Figure 3. PTCy BMT for RDEB Regimen. Timeline provided for pre-BMT 
conditioning chemotherapy and radiation (days and doses), BMT, GvHD prophylaxis, and MSC 
infusions. 
 
 
